2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Wednesday, November 8, 2017

9:00AM-10:30AM: Abstract Number: 2933

The Microvascular Niche Instructs Pathogenic T Cells in Medium and Large Vessel Vasculitis

Vasculitis III: Pathogenesis

9:00AM-10:30AM: Abstract Number: 2912

The Neural Correlates of Inflammation in RA: A Multi-Modal MRI Study

Rheumatoid Arthritis – Clinical Aspects VI: Comorbidities of Rheumatoid Arthritis

9:00AM-10:30AM: Abstract Number: 2913

the Periodontal Pathogen Aggregatibacter Actinomycetemcomitans Is Associated with Subclinical Coronary Atherosclerosis in Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects VI: Comorbidities of Rheumatoid Arthritis

9:00AM-10:30AM: Abstract Number: 2916

The Presence of a Large Number of Autoantibodies at Baseline Is Favourable for Early Treatment Response but Unfavourable for Drug-Free Remission in RA Patients

Rheumatoid Arthritis – Human Etiology and Pathogenesis II

9:00AM-10:30AM: Abstract Number: 2893

The Use of Natural Language Processing to Identify, Retrieve, Report, and Correct Observational Data on US Veterans Enrolled in the Veterans Affairs Rheumatoid Arthritis Registry

Health Services Research II: Methods and Technology in Care and Research

9:00AM-10:30AM: Abstract Number: 2930

Transforming Growth Factor Beta 3 (TGFB3) – a Novel Systemic Sclerosis Susceptibility Locus Involved in Fibrosis and Th17 Cell Development Identified By Genome-Wide Association Study in African Americans from the Genome Research in African American Scleroderma Patients Consortium

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics II

9:00AM-10:30AM: Abstract Number: 2899

Trapped Crystals in Synovial Fluid: Neutrophil Extracellular Traps (NETs) from Bench to Bed-Side

Metabolic and Crystal Arthropathies II: Mechanisms of Crystal Inflammation and Metabolism

9:00AM-10:30AM: Abstract Number: 2906

Use of Disease-Modifying Antirheumatic Drugs, Biologic Response Modifiers and Corticosteroids, and Subsequent Risk of Coccidioidomycosis Infection Among Medicare Beneficiaries

Miscellaneous Rheumatic and Inflammatory Diseases II

9:00AM-10:30AM: Abstract Number: 2929

WNT5A Promotes Tissue Fibrosis By Wnt/PCP-Dependent Activation of Latent TGF-β

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics II

11:00AM-12:30PM: Abstract Number: 2952

A Randomized Controlled Trial (RCT) of an Internet-Based Self-Management Program for Adolescents with Juvenile Idiopathic Arthritis (JIA)

Patient Outcomes, Preferences, and Attitudes III

11:00AM-12:30PM: Abstract Number: 2954

Achieving Balance and Diversity in Patient Engagement in Research: Perspectives from Patients

Patient Outcomes, Preferences, and Attitudes III

11:00AM-12:30PM: Abstract Number: 2967

Adding Ultrasound to the Treat-to-Target Strategy Shows No Benefit in Achievement of Remission: Results from the Biodam Cohort

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy V: Imaging and Cardiovascular Outcomes Therapy

11:00AM-12:30PM: Abstract Number: 2959

Are Patients with Overlap Features Different from Patients without? Results from the Juvenile Systemic Scleroderma Cohort Www.Juvenile-Scleroderma.Com

Pediatric Rheumatology – Clinical and Therapeutic Aspects III: Lupus, Dermatomyositis, and Scleroderma

11:00AM-12:30PM: Abstract Number: 2974

B Cell Binding Autoreactive VH4.34 Antibodies Are Specific to Lupus, Consist of Diverse Isotypes, and Are Associated with High Disease Activity and Lupus Nephritis

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis II

11:00AM-12:30PM: Abstract Number: 2961

Body Composition and Myokine Levels in Juvenile Dermatomyositis and Associations with Physical Function

Pediatric Rheumatology – Clinical and Therapeutic Aspects III: Lupus, Dermatomyositis, and Scleroderma

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].